The High Cost of Poor LFA Antibodies
Weak lateral flow assay antibodies, antigens, and conjugates can propagate failures from development to clinical use creating cascading scientific, manufacturing, commercial, and clinical consequences.
The Impact is Broad And Avoidable
Scientific Consequences
Variable performance across pathogen variants, serotypes, sample matrices, and testing conditions
Delays from failed verification and repeated bridging work
Increased cost from wasted materials and repeated testing
Lost development cycles due to inconsistent LFA analytical behavior
Commercial Consequences
Delayed launch timelines
Reduced competitiveness
Lost revenue opportunities
Manufacturing Consequences
Production delays caused by unstable lots
Wasted membranes, conjugates, and finished tests
Increased cost from troubleshooting and repeated QC
Disrupted supply commitments
Clinical Consequences
Reduced sensitivity and specificity
Transmission risks from false negatives
Trust your reagents. Clinical decisions depend on them.
You need rapid test antibodies, antigens, and conjugates that hold performance as pathogens evolve and manufacturing conditions change. Stable LFA reagents protect development timelines, reduce failed lots, and support clean verification and validation.
Arista Biologicals, a Fortis Life Sciences company, delivers reagents that maintain signal strength, control cross-reactivity, and demonstrate batch-to-batch reproducibility through validation, creating a smoother and more reliable path to market.
Supporting Reliable LFA Performance Across High-Priority Pathogens
NEW !
West Nile Virus
Well-characterized monoclonal antibodies against the West Nile virus envelope protein bind strongly to viral surface antigens from multiple lineages, enabling sensitive detection of intact virus while reducing cross‑reactivity with other flaviviruses.
| Catalog # | Name | Specificity | Action |
|---|---|---|---|
| ABWNV-0400 | Mouse anti-West Nile Virus | Envelope Protein | View Product Details > |
| ABWNV-0401 | Mouse anti-West Nile Virus, Clone 1 | Envelope Protein | View Product Details > |
| ABWNV-0402 | Mouse anti-West Nile Virus, Clone 2 | Envelope Protein | View Product Details > |
Dengue Virus (DENV 1–4)
Core NS1 antibodies evaluated for broad serotype coverage and minimal flavivirus cross-reactivity.
Helicobacter pylori
High-purity LFA reagents that maintain performance in complex gastric matrices.
Hepatitis B Virus (HBV)
High-affinity antibody detection in both vaccinated and unvaccinated populations, tested for stable performance in lateral flow formats.
Hepatitis C Virus (HCV)
Pan-genotypic LFA reagents that maintain sensitivity across global HCV diversity.
Human Immunodeficiency Virus (HIV)
Antigen targets selected for conserved epitope recognition and tested for consistent performance in lateral flow formats.
Influenza A and Influenza B
Antibodies targeting conserved nucleoprotein regions for reliable lateral flow assay performance across seasonal shifts.
Plasmodium Species (Malaria)
Reagents selected for reliable detection across species and for stable performance in low parasitemia settings.
SARS-CoV-2 (COVID-19) Reagents
Antibodies and antigens selected for consistent detection across emerging variants and stable signals in lateral flow systems
Treponema pallidum
Antigens are prepared to preserve structural integrity and support consistent detection across disease stages.
Related Resources
One Size Fits One - Advancing Infectious Disease Diagnostics With Custom Molecular Reagents
